KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin.Circ Heart FailPMID 41170566PMC127046672025-Dec0.98未发现恶性肿瘤人群证据。已完成
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41175888无 PMCID2025-Dec0.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。无 KM 图
The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41187466无 PMCID2025-Dec0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites.NEJM EvidPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41191932无 PMCID2025-Dec0.98未发现恶性肿瘤人群证据。无 KM 图
Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.Hum Vaccin Immunother已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:研究设计图;Figure 3:AI 判定为 flow diagram;Figure 4:AI 判定为 other。PMID 41194599PMC125993372025-Dec0.98未发现恶性肿瘤人群证据。无 KM 图
Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone-releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial.Eur Urol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41206286无 PMCID2025-Dec0.80The study meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result. However, it does not meet the 'time_to_event' criterion because the primary endpoint was changed to a binary response (PSA nadir) and the PFS endpoint, while mentioned, is not presented with Kaplan-Meier data or a hazard ratio suitable for digitization.无 KM 图
The Effectiveness of Plecanatide for Treating Constipation and Bloating in Patients Aged 18 to 40 Years With Irritable Bowel Syndrome: Utilization of a New Composite Trisymptom Endpoint.J Gastroenterol Hepatol已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other。PMID 41214272PMC126666122025-Dec0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials.Lancet PsychiatryPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41233083无 PMCID2025-Dec0.98未发现恶性肿瘤人群证据。无 KM 图
Frequent productive cough in COPD relates to exacerbation risk and treatment benefit from budesonide/glycopyrrolate/formoterol fumarate: a post hoc analysis of KRONOS.Respir MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41237914无 PMCID2025-Dec0.98未发现恶性肿瘤人群证据。无 KM 图
Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study.Lancet Glob HealthPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41240950无 PMCID2025-Dec0.98未发现恶性肿瘤人群证据。无 KM 图
Early onset, maintenance of effect, and day-/night-time findings following fezolinetant treatment for moderate to severe vasomotor symptoms associated with menopause: A pooled phase 3 analysis.MaturitasPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41259888无 PMCID2025-Dec0.98未发现恶性肿瘤人群证据。无 KM 图
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study.ESMO OpenPMID 41259897PMC126705412025-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Matching-adjusted indirect comparison of kidney function in patients with immunoglobulin A nephropathy treated with nefecon or sparsentan.J Comp Eff Res入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41263371PMC126796502025-Dec0.98未发现恶性肿瘤人群证据。无 KM 图
Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III study.ESMO OpenPMID 41270700PMC126700852025-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Tumor-Informed ctDNA in Guiding First-Line Immunochemotherapy in Advanced Non-Small Cell Lung Cancers.Adv Sci (Weinh)PMID 41287887PMC127526222025-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。部分完成
Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial.J Dermatolog Treat入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41288059无 PMCID2025-Dec0.98未发现恶性肿瘤人群证据。无 KM 图
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort.ESMO Open入排证据不足,等待复核:The record is a retrospective real-world cohort study reporting pathological complete response (pCR) rates, not a randomized trial with a primary/key secondary time-to-event efficacy endpoint. It does not meet the inclusion criteria for a drug-containing randomized trial with a time-to-event endpoint.PMID 41297161PMC126891992025-Dec0.45The record is a retrospective real-world cohort study reporting pathological complete response (pCR) rates, not a randomized trial with a primary/key secondary time-to-event efficacy endpoint. It does not meet the inclusion criteria for a drug-containing randomized trial with a time-to-event endpoint.无 KM 图
Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study.ESMO OpenAI 判定该论文不进入自动 KM 提取:This is a phase Ib study, not a phase III trial. While it includes a randomized component in one cohort, it is an early-phase, open-label study.PMID 41297162PMC126891932025-Dec0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。无 KM 图
Maintained improvement of outcomes related to skin clearance, itch, sleep and quality of life with baricitinib in adults with moderate-to-severe Atopic Dermatitis who were treated for up to 200 weeks in a randomized trial.J Dermatolog TreatPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41306112无 PMCID2025-Dec0.98未发现恶性肿瘤人群证据。无 KM 图
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41308673无 PMCID2025-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41308674无 PMCID2025-Dec0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41308676无 PMCID2025-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy and safety of Tan Yin Wan in preventing acute exacerbations of COPD: A multicenter, randomized, double-blind, placebo-controlled, phase Ⅳ clinical trial.Phytomedicine入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41313848无 PMCID2025-Dec0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet HIVPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41314741无 PMCID2025-Dec0.98未发现恶性肿瘤人群证据。无 KM 图
Therapeutic Modulation of IL-6/STAT-3 and Nitric Oxide by Fenofibrate in Patients With Ulcerative Colitis: A Randomized Controlled Pilot Study.Pharmacotherapy入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41330887无 PMCID2025-Dec0.98未发现恶性肿瘤人群证据。无 KM 图
Evaluation of Weight Gain and Overall Survival of Men Versus Women With Advanced Non-Small Cell Lung Cancer.J Cachexia Sarcopenia Muscle入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。PMID 41332393PMC126732742025-Dec0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
A Phase 3 study to assess the safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in healthy infants in the USA and Puerto Rico.Hum Vaccin Immunother已检查 7 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;captionless-figure:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;另有 2 张未列出。PMID 41337697PMC126882452025-Dec0.98未发现恶性肿瘤人群证据。无 KM 图
Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance).ESMO OpenPMID 41337859PMC127200832025-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial.ESMO OpenPMID 41337860PMC127200892025-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer.Clin Transl Sci疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图。PMID 41346252PMC126788632025-Dec0.45The report describes a Phase III randomized trial (Alliance A031201) but is an analysis of genetic associations with drug clearance (pharmacokinetics). It does not report or focus on a primary/key secondary time-to-event efficacy endpoint such as OS or PFS. The study is therefore ineligible.无 KM 图
No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes.Clin Transl Sci已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:ROC 图;FIGURE 2:AI 判定为 other。PMID 41390988PMC127021352025-Dec0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.Future OncolAI 判定该论文不进入自动 KM 提取:This record is a retrospective chart-review study analyzing outcomes after frontline treatment in the ALTA-1L trial, not a new Phase III RCT. It reports real-world data on subsequent treatments, not the primary Phase III trial results.PMID 41410381PMC127582422025-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Effects of rhEPO-Fc on chronic renal anemia in Chinese patients undergoing maintenance hemodialysis: a multicenter, randomized, open-label, and phase 3 study.Ren Fail已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图。PMID 41481110PMC127777502025-Dec0.98未发现恶性肿瘤人群证据。无 KM 图
Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study.Hum Vaccin Immunother已检查 7 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:AI 判定为 flow diagram;Figure 2:AI 判定为 flow diagram;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;另有 2 张未列出。PMID 41489614PMC127735642025-Dec0.98未发现恶性肿瘤人群证据。无 KM 图
Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage small-cell lung cancer: patient-reported outcomes in the RATIONALE-312 trial.Curr Med Res Opin疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41614649无 PMCID2025-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Impact of combined hormonal contraceptives and metformin on metabolic syndrome in women with hyperandrogenic polycystic ovary syndrome and obesity: The COMET-PCOS randomized clinical trial.PLoS Med已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig 1:AI 判定为 flow diagram;Fig 2:AI 判定为 other。PMID 41359669PMC126979812025-Dec0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials.Arthritis Res Ther已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other。PMID 41318485PMC127717032025-Nov-290.98未发现恶性肿瘤人群证据。无 KM 图
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies.RMD Open已检查 8 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other;另有 3 张未列出。PMID 41314667PMC127061122025-Nov-280.98未发现恶性肿瘤人群证据。无 KM 图
A composite endpoint for systemic sclerosis-associated interstitial lung disease: association with mortality in two clinical trial cohorts.Respir Res疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图。PMID 41316297PMC126618672025-Nov-280.98未发现恶性肿瘤人群证据。无 KM 图
Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.BloodPMID 40834881PMC128247012025-Nov-270.75This is a secondary, biomarker-focused analysis from the Myeloma-XI trial, examining the prognostic value of risk stratification. While the underlying trial is a Phase III randomized trial with drug interventions and time-to-event endpoints, this specific report does not present the primary or key secondary efficacy results of a drug-containing intervention vs. control. It is a subgroup/biomarker analysis.已完成
Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40888723无 PMCID2025-Nov-270.98未发现恶性肿瘤人群证据。无 KM 图
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.Blood AdvPMID 40763276PMC126572892025-Nov-250.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial.JAMAPMID 41123939PMC125476762025-Nov-250.98未发现恶性肿瘤人群证据。已完成
Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study.Nat CommunAI 判定该论文不进入自动 KM 提取:This is a phase II randomized controlled trial, not a phase III trial.PMID 41290609PMC126477242025-Nov-250.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。无 KM 图
[Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO-trial): a phase 3 multicentre stepped-wedge cluster-randomised noninferiority trial].Ned Tijdschr Geneeskd疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41725589无 PMCID2025-Nov-250.95The record describes a randomized Phase III trial with a primary time-to-event endpoint (OS) and reports results. However, the intervention under investigation is a management strategy (active surveillance) versus standard surgery following neoadjuvant chemoradiotherapy. The eligibility criterion of a 'drug-containing intervention' is not met, as the trial does not randomize patients to different drug regimens.无 KM 图
Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study.BMC NeurolPMID 41286676PMC126423642025-Nov-240.98未发现恶性肿瘤人群证据。已完成
Paclitaxel-Coated Balloon for the Treatment of Small Vessel In-Stent Restenosis: A Subgroup Analysis of the AGENT IDE Randomized Trial.JACC Cardiovasc IntervPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41297981无 PMCID2025-Nov-240.98未发现恶性肿瘤人群证据。无 KM 图
Daily Cigarette Abstinence and Smoking Rate With Varenicline: Relationships With Treatment, Craving, and Affect During the First Week of the Quit Attempt.Nicotine Tob Res已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other。PMID 40358028PMC126411812025-Nov-230.98未发现恶性肿瘤人群证据。无 KM 图
Long-term tolerability and effectiveness of eptinezumab in Japanese adults with chronic migraine: results of the 60-week open-label SUNSET trial.J Headache Pain入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41275111PMC126593202025-Nov-220.98未发现恶性肿瘤人群证据。无 KM 图
Long-term efficacy of migalastat in females with Fabry disease.J Med Genet入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40897525PMC127033072025-Nov-210.98未发现恶性肿瘤人群证据。无 KM 图